418 related articles for article (PubMed ID: 36585700)
1. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
[TBL] [Abstract][Full Text] [Related]
2. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
Routy B; Lenehan JG; Miller WH; Jamal R; Messaoudene M; Daisley BA; Hes C; Al KF; Martinez-Gili L; Punčochář M; Ernst S; Logan D; Belanger K; Esfahani K; Richard C; Ninkov M; Piccinno G; Armanini F; Pinto F; Krishnamoorthy M; Figueredo R; Thebault P; Takis P; Magrill J; Ramsay L; Derosa L; Marchesi JR; Parvathy SN; Elkrief A; Watson IR; Lapointe R; Segata N; Haeryfar SMM; Mullish BH; Silverman MS; Burton JP; Maleki Vareki S
Nat Med; 2023 Aug; 29(8):2121-2132. PubMed ID: 37414899
[TBL] [Abstract][Full Text] [Related]
3. Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients.
Fortman D; Avellan MGP; Hurd D; Schwartz M; Dubner H; Hewitt C; Berton S; Ernst S; Rose A; Zarour HWH; Davar D
Melanoma Res; 2023 Apr; 33(2):136-148. PubMed ID: 36806616
[TBL] [Abstract][Full Text] [Related]
4. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
Thompson NA; Stewart GD; Welsh SJ; Doherty GJ; Robinson MJ; Neville BA; Vervier K; Harris SR; Adams DJ; Dalchau K; Bruce D; Demiris N; Lawley TD; Corrie PG
BMC Cancer; 2022 Jan; 22(1):99. PubMed ID: 35073853
[TBL] [Abstract][Full Text] [Related]
5. The Gastrointestinal Microbiome and Immune Checkpoint Inhibitors: A Review of Human Interventional Studies Among Melanoma Patients.
Natarelli N; Aflatooni S; Boby A; Krenitsky A; Grichnik J
J Drugs Dermatol; 2024 Feb; 23(2):78-84. PubMed ID: 38306142
[TBL] [Abstract][Full Text] [Related]
6. Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers.
McQuade JL; Ologun GO; Arora R; Wargo JA
Curr Oncol Rep; 2020 Jun; 22(7):74. PubMed ID: 32577835
[TBL] [Abstract][Full Text] [Related]
7. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis.
Halsey TM; Thomas AS; Hayase T; Ma W; Abu-Sbeih H; Sun B; Parra ER; Jiang ZD; DuPont HL; Sanchez C; El-Himri R; Brown A; Flores I; McDaniel L; Ortega Turrubiates M; Hensel M; Pham D; Watowich SS; Hayase E; Chang CC; Jenq RR; Wang Y
Sci Transl Med; 2023 Jun; 15(700):eabq4006. PubMed ID: 37315113
[TBL] [Abstract][Full Text] [Related]
8. The Microbiome in Advanced Melanoma: Where Are We Now?
Fortman DD; Hurd D; Davar D
Curr Oncol Rep; 2023 Sep; 25(9):997-1016. PubMed ID: 37269504
[TBL] [Abstract][Full Text] [Related]
9. First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial).
Spreafico A; Heirali AA; Araujo DV; Tan TJ; Oliva M; Schneeberger PHH; Chen B; Wong MK; Stayner LA; Hansen AR; Saibil SD; Wang BX; Cochrane K; Sherriff K; Allen-Vercoe E; Xu W; Siu LL; Coburn B
Ann Oncol; 2023 Jun; 34(6):520-530. PubMed ID: 36863483
[TBL] [Abstract][Full Text] [Related]
10. Safety and feasibility of faecal microbiota transplantation for patients with Parkinson's disease: a protocol for a self-controlled interventional donor-FMT pilot study.
Vendrik KE; Chernova VO; Kuijper EJ; Terveer EM; van Hilten JJ; Contarino MF;
BMJ Open; 2023 Oct; 13(10):e071766. PubMed ID: 37798034
[TBL] [Abstract][Full Text] [Related]
11. Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors.
Shaikh FY; Gills JJ; Mohammad F; White JR; Stevens CM; Ding H; Fu J; Tam A; Blosser RL; Domingue JC; Larman TC; Chaft JE; Spicer JD; Reuss JE; Naidoo J; Forde PM; Ganguly S; Housseau F; Pardoll DM; Sears CL
Cancer Immunol Immunother; 2022 Oct; 71(10):2405-2420. PubMed ID: 35217892
[TBL] [Abstract][Full Text] [Related]
12. Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition.
Guardamagna M; Berciano-Guerrero MA; Villaescusa-González B; Perez-Ruiz E; Oliver J; Lavado-Valenzuela R; Rueda-Dominguez A; Barragán I; Queipo-Ortuño MI
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233289
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment.
Xu H; Cao C; Ren Y; Weng S; Liu L; Guo C; Wang L; Han X; Ren J; Liu Z
Front Immunol; 2022; 13():949490. PubMed ID: 36177041
[TBL] [Abstract][Full Text] [Related]
14. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Baruch EN; Youngster I; Ben-Betzalel G; Ortenberg R; Lahat A; Katz L; Adler K; Dick-Necula D; Raskin S; Bloch N; Rotin D; Anafi L; Avivi C; Melnichenko J; Steinberg-Silman Y; Mamtani R; Harati H; Asher N; Shapira-Frommer R; Brosh-Nissimov T; Eshet Y; Ben-Simon S; Ziv O; Khan MAW; Amit M; Ajami NJ; Barshack I; Schachter J; Wargo JA; Koren O; Markel G; Boursi B
Science; 2021 Feb; 371(6529):602-609. PubMed ID: 33303685
[TBL] [Abstract][Full Text] [Related]
15. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.
Renga G; Nunzi E; Pariano M; Puccetti M; Bellet MM; Pieraccini G; D'Onofrio F; Santarelli I; Stincardini C; Aversa F; Riuzzi F; Antognelli C; Gargaro M; Bereshchenko O; Ricci M; Giovagnoli S; Romani L; Costantini C
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236743
[TBL] [Abstract][Full Text] [Related]
16. Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study.
Jitsumura M; Cunningham AL; Hitchings MD; Islam S; Davies AP; Row PE; Riddell AD; Kinross J; Wilkinson TS; Jenkins GJ; Williams JG; Harris DA
BMJ Open; 2018 Oct; 8(10):e021987. PubMed ID: 30341117
[TBL] [Abstract][Full Text] [Related]
17. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.
Davar D; Dzutsev AK; McCulloch JA; Rodrigues RR; Chauvin JM; Morrison RM; Deblasio RN; Menna C; Ding Q; Pagliano O; Zidi B; Zhang S; Badger JH; Vetizou M; Cole AM; Fernandes MR; Prescott S; Costa RGF; Balaji AK; Morgun A; Vujkovic-Cvijin I; Wang H; Borhani AA; Schwartz MB; Dubner HM; Ernst SJ; Rose A; Najjar YG; Belkaid Y; Kirkwood JM; Trinchieri G; Zarour HM
Science; 2021 Feb; 371(6529):595-602. PubMed ID: 33542131
[TBL] [Abstract][Full Text] [Related]
18. Incongruence between dominant commensal donor microbes in recipient feces post fecal transplant and response to anti-PD-1 immunotherapy.
Koo H; Morrow CD
BMC Microbiol; 2021 Sep; 21(1):251. PubMed ID: 34544375
[TBL] [Abstract][Full Text] [Related]
19. Effect of fecal microbiota transplantation on primary hypertension and the underlying mechanism of gut microbiome restoration: protocol of a randomized, blinded, placebo-controlled study.
Fan L; Ren J; Chen Y; Wang Y; Guo Z; Bu P; Yang J; Ma W; Zhu B; Zhao Y; Cai J
Trials; 2022 Feb; 23(1):178. PubMed ID: 35209934
[TBL] [Abstract][Full Text] [Related]
20. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
